Prevalence and prognostic impact of the coexistence of cachexia and sarcopenia in older patients with heart failure

No study with an adequate patients' number has examined the relationship/overlap between sarcopenia and cachexia. We examined the prevalence of the overlap and prognostic implications of sarcopenia and cachexia in older patients with heart failure using well-accepted definitions. This was a pos...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2023-06, Vol.381, p.45-51
Main Authors: Fujimoto, Yudai, Maeda, Daichi, Kagiyama, Nobuyuki, Sunayama, Tsutomu, Dotare, Taishi, Jujo, Kentaro, Saito, Kazuya, Kamiya, Kentaro, Saito, Hiroshi, Ogasahara, Yuki, Maekawa, Emi, Konishi, Masaaki, Kitai, Takeshi, Iwata, Kentaro, Wada, Hiroshi, Hiki, Masaru, Kasai, Takatoshi, Nagamatsu, Hirofumi, Ozawa, Tetsuya, Izawa, Katsuya, Yamamoto, Shuhei, Aizawa, Naoki, Wakaume, Kazuki, Oka, Kazuhiro, Momomura, Shin-ichi, Matsue, Yuya
Format: Article
Language:English
Subjects:
Aged
cachexia
Cachexia - diagnosis
Cachexia - epidemiology
Cachexia - etiology
Heart failure
Heart Failure - complications
Heart Failure - diagnosis
Heart Failure - epidemiology
Humans
Older patients
Prevalence
Prognosis
Prospective Studies
Sarcopenia
Sarcopenia - diagnosis
Sarcopenia - epidemiology
Sarcopenia - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:No study with an adequate patients' number has examined the relationship/overlap between sarcopenia and cachexia. We examined the prevalence of the overlap and prognostic implications of sarcopenia and cachexia in older patients with heart failure using well-accepted definitions. This was a post-hoc sub-analysis of the FRAGILE-HF study, a prospective, multicenter, observational study conducted at 15 hospitals in Japan. In total, 905 hospitalized older patients were classified into four groups based on the presence or absence of cachexia and/or sarcopenia, which were defined according to the Evans and Asian Working Group for Sarcopenia criteria revised in 2019, respectively. The primary endpoint was 2-year all-cause mortality. Cachexia and sarcopenia prevalence rates were 32.7% and 22.7%, respectively. Patients were classified into the non-cachexia/non-sarcopenia (55.7%), cachexia/non-sarcopenia (21.7%), non-cachexia/sarcopenia (11.6%), and cachexia/sarcopenia (11.0%) groups. During the 2-year follow-up period after discharge, 158 (17.5%) all-cause deaths (124 cardiovascular deaths [CVD] and 34 non-CVD) were observed. The cachexia/sarcopenia group had the lowest body fat mass and exhibited significantly higher mortality rates (log-rank P 
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2023.03.035